Franziska Ruëff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Franziska Ruëff has a total of 767 co-authors. Here are the top co-authors by number of shared publications:
B. Przybilla
Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität, München, Germany
14 shared publicationsBernhard Przybilla
Department of Dermatology and Allergology, Ludwig-Maximilians-Universität, München, Germany
13 shared publications- Margitta Worm
Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy Charité—University Medical Center Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität Zu Berlin Berlin Germany
8 shared publications - Bernhard Przybilla
Ludwig-Maximilians-Universität
6 shared publications - Helmut Küchenhoff
Ludwig-Maximilians-Universität München
6 shared publications - Maria Beatrice Bilò
Department of Clinical and Molecular Sciences Università Politecnica delle Marche Ancona Italy
4 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Cofactors in Anaphylaxis: Insights From the European Anaphylaxis Registry
Background: The role of cofactors contributing to anaphylaxis severity remains unclear. Methods: We analysed data from the European Anaphylaxis Registry (2007–2024) to determine the impact of suspected cofactors on reaction severity. Adjusted odds ratios (aOR) were calculated for the number of organ systems affected, but also two severity classification systems (Ring/Messmer and Brown). Results: At least one suspected cofactor was reported in 8310 cases (49%) out of 16,915. Cofactors were less frequently suspected among younger patients (< 18 years: 26% and ≥ 18 years: 59%). Medication was the most common suspected cofactor in adults (41%), followed by exercise (27%), which was in parallel the most frequent suspected cofactor in children (19%). Emotional burden (children 3%/adults 8%), alcohol (0.4%/8%), sleep deprivation (0.5%/2%) and menstruation (2%/4%) were less commonly reported. We observed a trend between reaction severity and an increasing number of suspected cofactors. Among suspected cofactors, we observed consistent effects on anaphylaxis reaction severity for acute infections among children and alcohol consumption among adults in food‐induced reactions. Moreover, we identified an association between the presence of a suspected cofactor(s) and an increased time interval between exposure and onset of symptoms across all age groups in food‐induced anaphylaxis. Conclusions: Our data suggest an age‐dependent role of suspected cofactors in anaphylaxis severity. Clinicians should explore the presence of cofactors in patients who experienced anaphylaxis, in particular in those with prolonged time intervals between exposure and reaction onset.
- 23 October 2026
- Published by Wiley in Clinical & Experimental Allergy
Open AccessCofactors in Anaphylaxis: Insights From the European Anaphylaxis Registry
Background: The role of cofactors contributing to anaphylaxis severity remains unclear. Methods: We analysed data from the European Anaphylaxis Registry (2007–2024) to determine the impact of suspected cofactors on reaction severity. Adjusted odds ratios (aOR) were calculated for the number of organ systems affected, but also two severity classification systems (Ring/Messmer and Brown). Results: At least one suspected cofactor was reported in 8310 cases (49%) out of 16,915. Cofactors were less frequently suspected among younger patients (< 18 years: 26% and ≥ 18 years: 59%). Medication was the most common suspected cofactor in adults (41%), followed by exercise (27%), which was in parallel the most frequent suspected cofactor in children (19%). Emotional burden (children 3%/adults 8%), alcohol (0.4%/8%), sleep deprivation (0.5%/2%) and menstruation (2%/4%) were less commonly reported. We observed a trend between reaction severity and an increasing number of suspected cofactors. Among suspected cofactors, we observed consistent effects on anaphylaxis reaction severity for acute infections among children and alcohol consumption among adults in food‐induced reactions. Moreover, we identified an association between the presence of a suspected cofactor(s) and an increased time interval between exposure and onset of symptoms across all age groups in food‐induced anaphylaxis. Conclusions: Our data suggest an age‐dependent role of suspected cofactors in anaphylaxis severity. Clinicians should explore the presence of cofactors in patients who experienced anaphylaxis, in particular in those with prolonged time intervals between exposure and reaction onset.
- 27 June 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (9) , 784-794
Patient‐Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study
Background: Systemic mastocytosis (SM) is a clonal mast cell disease primarily driven by the KIT D816V mutation and often characterised by unpredictable and debilitating symptoms. The Perceptions Realities and Insights on Systemic Mastocytosis (PRISM) survey queried patient and provider perceptions of SM in Europe. Methods: PRISM (funded by Blueprint Medicines Corporation) was composed of two independent surveys: a 119‐item patient survey on diagnosis, symptom burden, quality of life (QoL) and work impact; and a 103‐item healthcare provider (HCP) survey on approaches to SM diagnosis and management. Results: Data were evaluated from 540 patient respondents from Italy ( n = 136), France ( n = 112), the UK ( n = 101), Germany ( n = 83), Spain ( n = 64), Austria ( n = 26) and Switzerland ( n = 18). Patients reported a high symptom burden and reduced physical functioning and mental health due to SM, despite taking, on average, seven medications. A majority of patients reported that SM impacted their ability to work (58.9%). A total of 618 HCP responses were collected from Italy ( n = 203), Germany ( n = 123), the UK ( n = 110), Austria ( n = 63), France ( n = 56), Switzerland ( n = 44) and Spain ( n = 19). Various HCP types reported treating patients with SM; the majority were haematologists/oncologists ( n = 167) and general practitioners ( n = 178). HCPs perceived that SM impacted their patients' QoL, with 54% reporting SM affected patients' lives ‘quite a bit’. The most frequently reported treatment goals were improving QoL and survival. Conclusions: PRISM is the largest international and first European survey to evaluate the burden of SM from both patient and HCP perspectives. Patients and HCPs perceived a high symptom burden, reduced QoL and reduced ability to work due to SM.
- 27 June 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (9) , 784-794
Patient‐Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study
Background: Systemic mastocytosis (SM) is a clonal mast cell disease primarily driven by the KIT D816V mutation and often characterised by unpredictable and debilitating symptoms. The Perceptions Realities and Insights on Systemic Mastocytosis (PRISM) survey queried patient and provider perceptions of SM in Europe. Methods: PRISM (funded by Blueprint Medicines Corporation) was composed of two independent surveys: a 119‐item patient survey on diagnosis, symptom burden, quality of life (QoL) and work impact; and a 103‐item healthcare provider (HCP) survey on approaches to SM diagnosis and management. Results: Data were evaluated from 540 patient respondents from Italy ( n = 136), France ( n = 112), the UK ( n = 101), Germany ( n = 83), Spain ( n = 64), Austria ( n = 26) and Switzerland ( n = 18). Patients reported a high symptom burden and reduced physical functioning and mental health due to SM, despite taking, on average, seven medications. A majority of patients reported that SM impacted their ability to work (58.9%). A total of 618 HCP responses were collected from Italy ( n = 203), Germany ( n = 123), the UK ( n = 110), Austria ( n = 63), France ( n = 56), Switzerland ( n = 44) and Spain ( n = 19). Various HCP types reported treating patients with SM; the majority were haematologists/oncologists ( n = 167) and general practitioners ( n = 178). HCPs perceived that SM impacted their patients' QoL, with 54% reporting SM affected patients' lives ‘quite a bit’. The most frequently reported treatment goals were improving QoL and survival. Conclusions: PRISM is the largest international and first European survey to evaluate the burden of SM from both patient and HCP perspectives. Patients and HCPs perceived a high symptom burden, reduced QoL and reduced ability to work due to SM.
- 1 January 2025
- Published by Springer Nature
- p. 1-8
So Confectionery and Candymakers
- Open Access
- 3 February 2024
- Published by Elsevier in JID Innovations
- Vol. 4 (3) , 100268
NOD/Scid IL2Rγnull Mice Reconstituted with PBMCs from Patients with Atopic Dermatitis or Psoriasis Vulgaris Reflect the Respective Phenotype
- 3 February 2024
- Published by Elsevier in JID Innovations
- Vol. 4 (3) , 100268
Open AccessNOD/Scid IL2Rγnull Mice Reconstituted with PBMCs from Patients with Atopic Dermatitis or Psoriasis Vulgaris Reflect the Respective Phenotype
- 11 January 2024
- Published by Springer Nature in Die Dermatologie
- Vol. 75 (2) , 126-133
Insektengiftallergien – Was wird sich ändern in Zeiten des globalen Wandels?
Zusammenfassung Hintergrund Hierzulande relevant für weiter reichende Stichreaktionen sind in erster Linie Honigbienen (Apis mellifera) und verschiedene Vespula-Arten (Wespen), seltener Hornissen (Vespa crabro), Hummeln, Feldwespe (Polistes) und Langkopfwespen (Dolichovespula). Fragestellung Es stellt sich die Frage, welche Auswirkungen intensive landwirtschaftliche Nutzung und Klimaänderungen auf Lebensbedingungen und Vorkommen von Hymenopteren haben und welche Folgen sich dadurch für Diagnostik und Therapie weiter reichender Stichreaktionen ergeben. Material und Methoden Es erfolgte eine Literaturrecherche. Ergebnisse Honig- und Wildbienen sind durch eingeschleppte Krankheiten, invasive Arten und Pestizide gefährdet. Ziel verbreiteter Imkertätigkeit ist der Schutz der Honigbienen, weswegen trotz immer wieder grassierenden Bienensterbens keine Abnahme von Stichen zu erwarten ist. Belegt ist in Deutschland eine Ausbreitung von wärmeliebenden Feldwespen von Süd nach Nord und eine Einwanderung einer Asiatischen Hornisse (Vespa velutina nigrithorax). Es ist nicht wahrscheinlich, dass durch diese Arten eine nennenswerte Zunahme von weiter reichenden Stichreaktionen erfolgen wird. Erstmals 2022 in Sizilien nachgewiesen wurden Nester der Roten Feuerameise (Solenopsis invicta), die ursprünglich in Südamerika beheimatet war. Es handelt sich um aggressive Insekten mit einem hohen Potenzial für auch weiter reichende unerwünschte Stichreaktionen. Diskussion Bei Anamnese und Diagnostik müssen invasive Insekten als Auslöser berücksichtigt werden. Diagnostika stehen nur für die Feststellung einer Polistes-Sensibilisierung zur Verfügung. Zur Behandlung einer Polistes-Allergie können aus dem europäischen Ausland Therapieallergene bezogen werden. Für die Diagnostik wie auch Therapie bei Verdacht auf eine Allergie gegen die Asiatische Hornisse wird aufgrund einer Kreuzreaktivität auf Diagnostika und Therapieallergene von Vespula spp. ausgewichen.
- 11 January 2024
- Published by Springer Nature in Die Dermatologie
- Vol. 75 (2) , 126-133
Insektengiftallergien – Was wird sich ändern in Zeiten des globalen Wandels?
Zusammenfassung Hintergrund Hierzulande relevant für weiter reichende Stichreaktionen sind in erster Linie Honigbienen (Apis mellifera) und verschiedene Vespula-Arten (Wespen), seltener Hornissen (Vespa crabro), Hummeln, Feldwespe (Polistes) und Langkopfwespen (Dolichovespula). Fragestellung Es stellt sich die Frage, welche Auswirkungen intensive landwirtschaftliche Nutzung und Klimaänderungen auf Lebensbedingungen und Vorkommen von Hymenopteren haben und welche Folgen sich dadurch für Diagnostik und Therapie weiter reichender Stichreaktionen ergeben. Material und Methoden Es erfolgte eine Literaturrecherche. Ergebnisse Honig- und Wildbienen sind durch eingeschleppte Krankheiten, invasive Arten und Pestizide gefährdet. Ziel verbreiteter Imkertätigkeit ist der Schutz der Honigbienen, weswegen trotz immer wieder grassierenden Bienensterbens keine Abnahme von Stichen zu erwarten ist. Belegt ist in Deutschland eine Ausbreitung von wärmeliebenden Feldwespen von Süd nach Nord und eine Einwanderung einer Asiatischen Hornisse (Vespa velutina nigrithorax). Es ist nicht wahrscheinlich, dass durch diese Arten eine nennenswerte Zunahme von weiter reichenden Stichreaktionen erfolgen wird. Erstmals 2022 in Sizilien nachgewiesen wurden Nester der Roten Feuerameise (Solenopsis invicta), die ursprünglich in Südamerika beheimatet war. Es handelt sich um aggressive Insekten mit einem hohen Potenzial für auch weiter reichende unerwünschte Stichreaktionen. Diskussion Bei Anamnese und Diagnostik müssen invasive Insekten als Auslöser berücksichtigt werden. Diagnostika stehen nur für die Feststellung einer Polistes-Sensibilisierung zur Verfügung. Zur Behandlung einer Polistes-Allergie können aus dem europäischen Ausland Therapieallergene bezogen werden. Für die Diagnostik wie auch Therapie bei Verdacht auf eine Allergie gegen die Asiatische Hornisse wird aufgrund einer Kreuzreaktivität auf Diagnostika und Therapieallergene von Vespula spp. ausgewichen.
- Open Access
- 1 January 2024
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 8 (01) , 299-303
Diagnostic measures in patients with severe insect sting reactions and elevated baseline serum tryptase levels
Mastocytosis or an elevated basal serum tryptase (bST) level are known risk factors for patients with insect venom allergy. We report on 3 patients with a history of severe anaphylactic insect sting reactions who underwent a detailed workup for insect venom allergy before starting venom immunotherapy. In addition to insect venom sensitization, an elevated concentration of bST (15.5, 20.8, and 23.2 µg/L) was found in all cases. There was no evidence of mastocytosis in the skin (MIS). Further testing revealed hereditary α-hypertryptasemia (HαT) in 2 patients and a D816V mutation by liquid biopsy in 1 patient, which is a minor diagnostic criterion for indolent systemic mastocytosis. Even without iliac crest puncture, causes of elevated bST can be narrowed down with minimally invasive diagnostic measures. As this has practical implications, patients with elevated bST should always undergo further work-up to determine the cause of this abnormal finding.
- 1 January 2024
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 8 (01) , 299-303
Open AccessDiagnostic measures in patients with severe insect sting reactions and elevated baseline serum tryptase levels
Mastocytosis or an elevated basal serum tryptase (bST) level are known risk factors for patients with insect venom allergy. We report on 3 patients with a history of severe anaphylactic insect sting reactions who underwent a detailed workup for insect venom allergy before starting venom immunotherapy. In addition to insect venom sensitization, an elevated concentration of bST (15.5, 20.8, and 23.2 µg/L) was found in all cases. There was no evidence of mastocytosis in the skin (MIS). Further testing revealed hereditary α-hypertryptasemia (HαT) in 2 patients and a D816V mutation by liquid biopsy in 1 patient, which is a minor diagnostic criterion for indolent systemic mastocytosis. Even without iliac crest puncture, causes of elevated bST can be narrowed down with minimally invasive diagnostic measures. As this has practical implications, patients with elevated bST should always undergo further work-up to determine the cause of this abnormal finding.
- 25 December 2023
- Published by Wiley in Contact Dermatitis
- Vol. 90 (5) , 470-478
Declining frequency of sensitization to fragrance mixes I and II: IVDK‐data of the years 2012–2021
Background: EU Commission Regulation 2017/1410 prohibits using atranol and chloroatranol, the main allergens in Evernia prunastri (oakmoss), and hydroxyisohexyl 3‐cyclohexene carboxaldehyde (HICC) in cosmetic products. Oakmoss absolute is contained in fragrance mix (FM) I and HICC in FM II which are patch tested as screening mixtures in the baseline series.Objective: To describe the time trends of reaction frequencies to both FMs as well as to their components in FM‐positive patients.Methods: Retrospective analysis of data from the Information Network of Departments of Dermatology (IVDK), 2012–2021.Results: Positive reactions to FM I (FM II) declined from 9.1% (4.7%) in 2012 to 4.6% (3.0%) in 2021. Full breakdown tests were performed in 24% (FM I) and 31% (FM II), respectively, of the mix‐positive patients. From this data, frequencies of sensitization to the 14 single fragrances of FM I and FM II were calculated. For the majority, a decline was noted from 2012/2013 to 2020/2021, for oakmoss absolute 1.9%–0.8% and for HICC 1.8%–0.9%.Conclusion: EU Commission Regulation 2017/1410 was an effective measure. However, our data have some limitations, possibly causing underestimation of sensitization frequencies to fragrances.
- 25 December 2023
- Published by Wiley in Contact Dermatitis
- Vol. 90 (5) , 470-478
Declining frequency of sensitization to fragrance mixes I and II: IVDK‐data of the years 2012–2021
Background: EU Commission Regulation 2017/1410 prohibits using atranol and chloroatranol, the main allergens in Evernia prunastri (oakmoss), and hydroxyisohexyl 3‐cyclohexene carboxaldehyde (HICC) in cosmetic products. Oakmoss absolute is contained in fragrance mix (FM) I and HICC in FM II which are patch tested as screening mixtures in the baseline series.Objective: To describe the time trends of reaction frequencies to both FMs as well as to their components in FM‐positive patients.Methods: Retrospective analysis of data from the Information Network of Departments of Dermatology (IVDK), 2012–2021.Results: Positive reactions to FM I (FM II) declined from 9.1% (4.7%) in 2012 to 4.6% (3.0%) in 2021. Full breakdown tests were performed in 24% (FM I) and 31% (FM II), respectively, of the mix‐positive patients. From this data, frequencies of sensitization to the 14 single fragrances of FM I and FM II were calculated. For the majority, a decline was noted from 2012/2013 to 2020/2021, for oakmoss absolute 1.9%–0.8% and for HICC 1.8%–0.9%.Conclusion: EU Commission Regulation 2017/1410 was an effective measure. However, our data have some limitations, possibly causing underestimation of sensitization frequencies to fragrances.
- 1 October 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 46 (10) , 649-689
Diagnose und Therapie der Bienen- und Wespengiftallergie
- 1 October 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 46 (10) , 649-689
Diagnose und Therapie der Bienen- und Wespengiftallergie
- Open Access
- 1 January 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 7 (1) , 154-190
Diagnosis and treatment of Hymenoptera venom allergy
Hymenoptera venom (HV) is injected into the skin during a sting by Hymenoptera such as bees or wasps. Some components of HV are potential allergens and can cause large local and/or systemic allergic reactions (SAR) in sensitized individuals. During their lifetime, ~ 3% of the general population will develop SAR following a Hymenoptera sting. This guideline presents the diagnostic and therapeutic approach to SAR following Hymenoptera stings. Symptomatic therapy is usually required after a severe local reaction, but specific diagnosis or allergen immunotherapy (AIT) with HV (VIT) is not necessary. When taking a patient’s medical history after SAR, clinicians should discuss possible risk factors for more frequent stings and more severe anaphylactic reactions. The most important risk factors for more severe SAR are mast cell disease and, especially in children, uncontrolled asthma. Therefore, if the SAR extends beyond the skin (according to the Ring and Messmer classification: grade > I), the baseline serum tryptase concentration shall be measured and the skin shall be examined for possible mastocytosis. The medical history should also include questions specific to asthma symptoms. To demonstrate sensitization to HV, allergists shall determine concentrations of specific IgE antibodies (sIgE) to bee and/or vespid venoms, their constituents and other venoms as appropriate. If the results are negative less than 2 weeks after the sting, the tests shall be repeated (at least 4 – 6 weeks after the sting). If only sIgE to the total venom extracts have been determined, if there is double sensitization, or if the results are implausible, allergists shall determine sIgE to the different venom components. Skin testing may be omitted if in-vitro methods have provided a definitive diagnosis. If neither laboratory diagnosis nor skin testing has led to conclusive results, additional cellular testing can be performed. Therapy for HV allergy includes prophylaxis of reexposure, patient self treatment measures (including use of rescue medication) in the event of re-stings, and VIT. Following a grade I SAR and in the absence of other risk factors for repeated sting exposure or more severe anaphylaxis, it is not necessary to prescribe an adrenaline auto-injector (AAI) or to administer VIT. Under certain conditions, VIT can be administered even in the presence of previous grade I anaphylaxis, e.g., if there are additional risk factors or if quality of life would be reduced without VIT. Physicians should be aware of the contraindications to VIT, although they can be overridden in justified individual cases after weighing benefits and risks. The use of β-blockers and ACE inhibitors is not a contraindication to VIT. Patients should be informed about possible interactions. For VIT, the venom extract shall be used that, according to the patient’s history and the results of the allergy diagnostics, was the trigger of the disease. If, in the case of double sensitization and an unclear history regarding the trigger, it is not possible to determine the culprit venom even with additional diagnostic procedures, VIT shall be performed with both venom extracts. The standard maintenance dose of VIT is 100 µg HV. In adult patients with bee venom allergy and an increased risk of sting exposure or particularly severe anaphylaxis, a maintenance dose of 200 µg can be considered from the start of VIT. Administration of a non-sedating H1-blocking antihistamine can be considered to reduce side effects. The maintenance dose should be given at 4-weekly intervals during the first year and, following the manufacturer’s instructions, every 5 – 6 weeks from the second year, depending on the preparation used; if a depot preparation is used, the interval can be extended to 8 weeks from the third year onwards. If significant recurrent systemic reactions occur during VIT, clinicians shall identify and as possible eliminate co-factors that promote these reactions. If this is not possible or if there are no such co-factors, if prophylactic administration of an H1-blocking antihistamine is not effective, and if a higher dose of VIT has not led to tolerability of VIT, physicians should should consider additional treatment with an anti IgE antibody such as omalizumab as off lable use. For practical reasons, only a small number of patients are able to undergo sting challenge tests to check the success of the therapy, which requires in-hospital monitoring and emergency standby. To perform such a provocation test, patients must have tolerated VIT at the planned maintenance dose. In the event of treatment failure while on treatment with an ACE inhibitor, physicians should consider discontinuing the ACE inhibitor. In the absence of tolerance induction, physicians shall increase the maintenance dose (200 µg to a maximum of 400 µg in adults, maximum of 200 µg HV in children). If increasing the maintenance dose does not provide adequate protection and there are risk factors for a severe anaphylactic reaction, physicians should consider a co-medication based on an anti-IgE antibody (omalizumab; off-label use) during the insect flight season. In patients without specific risk factors, VIT can be discontinued after 3 – 5 years if maintenance therapy has been tolerated without recurrent anaphylactic events. Prolonged or permanent VIT can be considered in patients with mastocytosis, a history of cardiovascular or respiratory arrest due to Hymenoptera sting (severity grade IV), or other specific constellations associated with an increased individual risk of recurrent and/or severe SAR (e.g., hereditary α-tryptasemia). In cases of strongly increased, unavoidable insect exposure, adults may receive VIT until the end of intense contact. The prescription of an AAI can be omitted in patients with a history of SAR grade I and II when the maintenance dose of VIT has been reached and...
- 1 January 2023
- Published by Dustri-Verlag Dr. Karl Feistle in Allergologie select
- Vol. 7 (1) , 154-190
Open AccessDiagnosis and treatment of Hymenoptera venom allergy
Hymenoptera venom (HV) is injected into the skin during a sting by Hymenoptera such as bees or wasps. Some components of HV are potential allergens and can cause large local and/or systemic allergic reactions (SAR) in sensitized individuals. During their lifetime, ~ 3% of the general population will develop SAR following a Hymenoptera sting. This guideline presents the diagnostic and therapeutic approach to SAR following Hymenoptera stings. Symptomatic therapy is usually required after a severe local reaction, but specific diagnosis or allergen immunotherapy (AIT) with HV (VIT) is not necessary. When taking a patient’s medical history after SAR, clinicians should discuss possible risk factors for more frequent stings and more severe anaphylactic reactions. The most important risk factors for more severe SAR are mast cell disease and, especially in children, uncontrolled asthma. Therefore, if the SAR extends beyond the skin (according to the Ring and Messmer classification: grade > I), the baseline serum tryptase concentration shall be measured and the skin shall be examined for possible mastocytosis. The medical history should also include questions specific to asthma symptoms. To demonstrate sensitization to HV, allergists shall determine concentrations of specific IgE antibodies (sIgE) to bee and/or vespid venoms, their constituents and other venoms as appropriate. If the results are negative less than 2 weeks after the sting, the tests shall be repeated (at least 4 – 6 weeks after the sting). If only sIgE to the total venom extracts have been determined, if there is double sensitization, or if the results are implausible, allergists shall determine sIgE to the different venom components. Skin testing may be omitted if in-vitro methods have provided a definitive diagnosis. If neither laboratory diagnosis nor skin testing has led to conclusive results, additional cellular testing can be performed. Therapy for HV allergy includes prophylaxis of reexposure, patient self treatment measures (including use of rescue medication) in the event of re-stings, and VIT. Following a grade I SAR and in the absence of other risk factors for repeated sting exposure or more severe anaphylaxis, it is not necessary to prescribe an adrenaline auto-injector (AAI) or to administer VIT. Under certain conditions, VIT can be administered even in the presence of previous grade I anaphylaxis, e.g., if there are additional risk factors or if quality of life would be reduced without VIT. Physicians should be aware of the contraindications to VIT, although they can be overridden in justified individual cases after weighing benefits and risks. The use of β-blockers and ACE inhibitors is not a contraindication to VIT. Patients should be informed about possible interactions. For VIT, the venom extract shall be used that, according to the patient’s history and the results of the allergy diagnostics, was the trigger of the disease. If, in the case of double sensitization and an unclear history regarding the trigger, it is not possible to determine the culprit venom even with additional diagnostic procedures, VIT shall be performed with both venom extracts. The standard maintenance dose of VIT is 100 µg HV. In adult patients with bee venom allergy and an increased risk of sting exposure or particularly severe anaphylaxis, a maintenance dose of 200 µg can be considered from the start of VIT. Administration of a non-sedating H1-blocking antihistamine can be considered to reduce side effects. The maintenance dose should be given at 4-weekly intervals during the first year and, following the manufacturer’s instructions, every 5 – 6 weeks from the second year, depending on the preparation used; if a depot preparation is used, the interval can be extended to 8 weeks from the third year onwards. If significant recurrent systemic reactions occur during VIT, clinicians shall identify and as possible eliminate co-factors that promote these reactions. If this is not possible or if there are no such co-factors, if prophylactic administration of an H1-blocking antihistamine is not effective, and if a higher dose of VIT has not led to tolerability of VIT, physicians should should consider additional treatment with an anti IgE antibody such as omalizumab as off lable use. For practical reasons, only a small number of patients are able to undergo sting challenge tests to check the success of the therapy, which requires in-hospital monitoring and emergency standby. To perform such a provocation test, patients must have tolerated VIT at the planned maintenance dose. In the event of treatment failure while on treatment with an ACE inhibitor, physicians should consider discontinuing the ACE inhibitor. In the absence of tolerance induction, physicians shall increase the maintenance dose (200 µg to a maximum of 400 µg in adults, maximum of 200 µg HV in children). If increasing the maintenance dose does not provide adequate protection and there are risk factors for a severe anaphylactic reaction, physicians should consider a co-medication based on an anti-IgE antibody (omalizumab; off-label use) during the insect flight season. In patients without specific risk factors, VIT can be discontinued after 3 – 5 years if maintenance therapy has been tolerated without recurrent anaphylactic events. Prolonged or permanent VIT can be considered in patients with mastocytosis, a history of cardiovascular or respiratory arrest due to Hymenoptera sting (severity grade IV), or other specific constellations associated with an increased individual risk of recurrent and/or severe SAR (e.g., hereditary α-tryptasemia). In cases of strongly increased, unavoidable insect exposure, adults may receive VIT until the end of intense contact. The prescription of an AAI can be omitted in patients with a history of SAR grade I and II when the maintenance dose of VIT has been reached and...
- Open Access
Different phenotypes of drug‐induced anaphylaxis—Data from the European Anaphylaxis Registry
Background: Drugs are a frequent cause of severe anaphylactic reactions. Here, we analyze a large dataset on drug induced anaphylaxis regarding elicitors, risk factors, symptoms, and treatment. Methods: Data from the European Anaphylaxis Registry (2007–2019) with 1815 reported cases of drug‐induced anaphylaxis were studied accordingly. Results: Drugs are the third most frequent cause of anaphylaxis reported in the Anaphylaxis Registry. Among the eliciting groups of drugs analgesics and antibiotics were far most often reported. Female and senior patients were more frequently affected, while the number of children with DIA was low. DIA patients had symptoms affecting the skin and mucous membranes ( n = 1525, 84.02%), the respiratory ( n = 1300, 71.63%), the cardiovascular ( n = 1251, 68.93%) and the gastrointestinal system ( n = 549, 30.25%). Drugs caused significant more severe reactions, occurred more often in medical facilities and led to increased hospitalization rates in comparison to food and insect venom induced anaphylaxis. Adrenaline was used more often in patients with DIA than in anaphylaxis due to other causes. Patients with skin symptoms received more antihistamines and corticosteroids in the acute treatment, while gastrointestinal symptoms led to less adrenaline use. Conclusion: The study contributes to a better understanding of DIA, with a large number of cases from Europe supporting previous data, e.g., analgesics and antibiotics being the most frequent culprits for DIA. Female gender and higher age are relevant risk factors and despite clear recommendations, the emergency treatment of DIA is not administered according to the guidelines.
Open AccessDifferent phenotypes of drug‐induced anaphylaxis—Data from the European Anaphylaxis Registry
Background: Drugs are a frequent cause of severe anaphylactic reactions. Here, we analyze a large dataset on drug induced anaphylaxis regarding elicitors, risk factors, symptoms, and treatment. Methods: Data from the European Anaphylaxis Registry (2007–2019) with 1815 reported cases of drug‐induced anaphylaxis were studied accordingly. Results: Drugs are the third most frequent cause of anaphylaxis reported in the Anaphylaxis Registry. Among the eliciting groups of drugs analgesics and antibiotics were far most often reported. Female and senior patients were more frequently affected, while the number of children with DIA was low. DIA patients had symptoms affecting the skin and mucous membranes ( n = 1525, 84.02%), the respiratory ( n = 1300, 71.63%), the cardiovascular ( n = 1251, 68.93%) and the gastrointestinal system ( n = 549, 30.25%). Drugs caused significant more severe reactions, occurred more often in medical facilities and led to increased hospitalization rates in comparison to food and insect venom induced anaphylaxis. Adrenaline was used more often in patients with DIA than in anaphylaxis due to other causes. Patients with skin symptoms received more antihistamines and corticosteroids in the acute treatment, while gastrointestinal symptoms led to less adrenaline use. Conclusion: The study contributes to a better understanding of DIA, with a large number of cases from Europe supporting previous data, e.g., analgesics and antibiotics being the most frequent culprits for DIA. Female gender and higher age are relevant risk factors and despite clear recommendations, the emergency treatment of DIA is not administered according to the guidelines.